Association of Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism With Serum Level and Development of Pulmonary Complications Following Esophagectomy

Abstract

An ACE insertion/deletion polymorphism might modulate the function of ACE gene and play a role in affecting individual susceptibility to pulmonary injury following esophagectomy in patients of esophageal cancer.

Influence of Visceral Obesity for Postoperative Pulmonary Complications After Pancreaticoduodenectomy

“…25 PPCs were defined as pneumonia with evidence by radiologic pulmonary infiltrates and/or the presence of pathogenic bacteria in the sputum culture, and pulmonary atelectasis required frequent bronchoscopic toilet or prolonged ventilator support. 26 Pulmonary edema, pulmonary embolus, and acute respiratory distress syndrome were excluded, similar to previous reports. 27 Other postoperative complications were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v.3.0).…”

Gene Polymorphisms and Febrile Neutropenia in Acute Leukemia—No Association with IL-4, CCR-5, IL-1RA, but the MBL-2, ACE, and TLR-4 Are Associated with the Disease in Turkish Patients: A Preliminary Study

“…ACE converts angiotensin I to angiotensin II (AT2) and inactivates bradykinin (Lee et al, 2005). The I/D polymorphism of the human ACE gene, characterized by the presence (I) or absence (D) of a 287 bp fragment in intron 16, has been shown to modulate ACE activity both in the circulation and in the tissue.…”

Lack of association between ACE insertion/deletion polymorphism and lung cancer: A meta-analysis

“…Previous reports indicated that plasma ACE levels were partly regulated by I/D polymorphism in intron-16, with DD homozygotes having roughly twice the ACE levels of II homozygotes. 22 In recent years, more and more publications suggested that the ACE I/D polymorphism is related to lung cancer risk. [11][12][13][14][15][18][19][20] Cheon et al 11 were the first to report the association of the ACE I/D polymorphism with lung cancer.…”